Global economic costs due to vivax malaria and the potential impact of its radical cure: A modelling study.

ABSTRACT:

Background

In 2017, an estimated 14 million cases of Plasmodium vivax malaria were reported from Asia, Central and South America, and the Horn of Africa. The clinical burden of vivax malaria is largely driven by its ability to form dormant liver stages (hypnozoites) that can reactivate to cause recurrent episodes of malaria. Elimination of both the blood and liver stages of the parasites ("radical cure") is required to achieve a sustained clinical response and prevent ongoing transmission of the parasite. Novel treatment options and point-of-care diagnostics are now available to ensure that radical cure can be administered safely and effectively. We quantified the global economic cost of vivax malaria and estimated the potential cost benefit of a policy of radical cure after testin

SUBMITTER: Devine A 

PROVIDER: S-EPMC8168905 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature